Hepion Pharmaceuticals, Inc. (OTC:HEPA)
| Market Cap | $1.39M+80.3% |
| Revenue (ttm) | $0 |
| Net Income | -$7.30M+20.4% |
| EPS | -$0.27+98.0% |
| Shares Out | 11.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,803 |
| Open | $0.12 |
| Previous Close | $0.10 |
| Day's Range | $0.09 - $0.12 |
| 52-Week Range | $0.03 - $0.22 |
| Beta | 1.69 |
| Analysts | Hold |
| Price Target | $70.00(+58723.53%) |
| Earnings Date | Mar 3, 2027 |
About HEPA
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. Stock Analysis — InsiderScore
Hepion Pharmaceuticals, Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 97th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Hepion Pharmaceuticals, Inc. bought $10.0K of stock across 1 purchase in the last 90 days, the largest of them $10.0K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 3, 2027Earnings report
$HEPA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HEPA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HEPA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HEPA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HEPA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HEPA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from HEPA’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+29.2 since Sep 17Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
